Source link : https://www.newshealth.biz/health-news/anti-cd38-based-quadruplet-improves-outcomes-in-transplant-ineligible-myeloma/
(MedPage Today) — Daratumumab (Darzalex) plus the standard triplet of bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (D-VRd) significantly improved clinical outcomes versus VRd alone in patients with transplant-ineligible or… Source link : https://www.medpagetoday.com/hematologyoncology/myeloma/114159 Author : Publish date : 2025-02-10 21:08:40 Copyright for syndicated content belongs to the linked Source.
Author : News Health
Publish date : 2025-02-10 21:08:40
Copyright for syndicated content belongs to the linked Source.
inHealth